A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

Inclusion Criteria: * Diagnosis of CKD with screening eGFR (average of Screen A and Screen B eGFR values) ≥ 20 to \< 60 mL/min/1.73 m2 * Patient must meet at least one of the following criteria: 1. UACR ≥ 300 mg/g; OR 2. eGFR decline at a rate of ≥ 4 mL/min/1.73 m2 in prior year; OR 3. Hematuria defined as \> 5-10 red blood cells (RBCs) per high power field (HPF, manual method), or documented history of positive urinary dipstick for blood in prior year, or macroscopic hematuria in prior 3 years; * Systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 90 mmHg at Screen A visit after a period of rest (≥ 5 minutes); * Treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or an angiotensin II receptor blocker (ARB) at the maximally tolerated labeled daily dose for at least 6 weeks prior to the Screen A visit and with no anticipated changes to dose(s) during study participation. * Able to swallow capsules - Exclusion Criteria: * Prior exposure to bardoxolone methyl; * CKD secondary to or associated with any of the following: 1. History of rapidly progressive glomerulonephritis (RPGN) 2. Glomerulonephritis requiring immunosuppression in the last 6 months prior to Screen A; * Concomitant use of tolvaptan. * Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to Day 1 or anticipated need for immunosuppression during the study; * Patients currently taking a sodium/glucose cotransporter-2 inhibitor (SGLT2i), requiring dose adjustments within 12 weeks prior to Day 1 or if dose is anticipated to change during study participation; * B-type natriuretic peptide (BNP) level \> 200 pg/mL at Screen A visit; * Uncontrolled diabetes (HbA1c \> 11.0%) at Screen A visit; * Serum albumin \< 3 g/dL at Screen A visit; * Kidney or any other solid organ transplant recipient or a planned transplant during the study; * Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening; * History of clinically significant cardiac disease; * Systolic blood pressure \< 90 mmHg at Screen A visit after a period of rest; * Body mass index \< 18.5 kg/m2 at the Screen A visit; * History of malignancy within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas; * Coronavirus disease 2019 (COVID-19) diagnosis within 3 months prior to Screen A or have ever required COVID-19 related hospitalization; * Participation in other interventional clinical studies within 3 months (or if relevant 5 half-lives of that study medication, whichever is the longer) prior to Screen B; * Unwilling to practice acceptable methods of birth control; * Women who are pregnant or breastfeeding.